{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-276022","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.708651+00:00","generated_at":"2026-05-16T21:29:22.518465+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Coya Therapeutics reports Q3 net loss of $2.1M; IND accepted for COYA 302 in ALS","bullets":["Net loss of $2.1M for Q3 2025 improved from $4.0M loss in Q3 2024; cash and equivalents at $28.1M.","FDA accepted IND for COYA 302 in ALS; ALSTARS Phase 2 trial launched with up to 25 sites.","Closed $23.0M upsized public offering; cash runway extended into second half of 2027.","Received $4.2M milestone from Dr. Reddy's for IND approval; additional $4.2M due on first dosing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-276022","json":"https://secwatch.observer/filing/0001193125-25-276022.json","markdown":"https://secwatch.observer/filing/0001193125-25-276022.md","text":"https://secwatch.observer/filing/0001193125-25-276022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312525276022/0001193125-25-276022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312525276022/coya-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:29:22.518465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}